New pumps drive growth, but margins remain thinner
- U.S. revenue grew 13 percent in the first quarter of 2027, driven by the MiniMed Flex launch.
- The main profit engine is a base of pumps that drives repeat sales of sensors, infusion sets, and reservoirs.
- MiniMed Flex and MiniMed Go give the company new ways to win users, with new pumps sold up over 20 percent year over year.
- The pipeline includes the MiniMed Fit patch pump and the Vivera closed loop algorithm, both slated for 2027.
- The bear case centers on pricing pressure in continuous glucose monitoring and lower margins as sensors become a bigger mix.
New pumps lift sales, margins test profits
MiniMed is a diabetes device company with a large installed base. Its flagship MiniMed 780G system combines an insulin pump, a continuous glucose monitor, and software that helps dose insulin. That base matters because many users keep buying single use sensors and supplies after the first pump sale.
The bull case focuses on accelerating product adoption. The MiniMed Flex launch drove a 13 percent increase in U.S. revenue during the first quarter of fiscal 2027, with U.S. new pumps sold up more than 20 percent year over year. The pipeline adds more fuel, with the Fit patch pump and the Vivera algorithm expected in 2027.
The bear case revolves around profitability. Continuous glucose monitors carry lower profit margins than pumps and other consumables, and the pharmacy channel is more rebate heavy. The company is also newly public after a Medtronic carve out, with Medtronic still owning about 90 percent of the shares. That makes costs, governance, and any future Medtronic divestment key watch points.
A pump base that keeps buying
MiniMed makes money from reusable devices and repeat use supplies. Pumps and smart insulin pens can stay with a patient for a year or more. Pumps are often replaced every four to five years, depending on payer rules and geography.
The repeat business comes from sensors, infusion sets, and reservoirs. These are single use products that patients replace often to keep an automated insulin delivery system working. If MiniMed grows its user base and raises sensor attachment, sales can grow even when pump sales are choppy.
There are two weak spots in this model. First, sensors can be lower margin than pumps, so faster sensor growth can pressure gross profit. Second, pharmacy coverage can make pricing tougher because rivals can use rebates to lower patient costs and limit competing coverage.
MiniMed is also still separating from Medtronic. The company relies on its former parent for transition services and manufacturing arrangements. As a stand alone business, it faces restructuring costs and potential one time milestone charges.
The diabetes toolkit
MiniMed 780G AID system
This is the flagship automated insulin delivery system. It links a pump, sensor, infusion supplies, and a dosing algorithm.
MiniMed Flex
Flex is a discreet, smartphone controlled insulin pump. It recently launched in the U.S. and drove a significant increase in new pump sales.
CGM sensors
The sensor lineup includes Simplera Sync and Instinct. Sensor sales are growing as attachment rises across the pump base.
Infusion sets and reservoirs
These consumables keep pump systems running. They are important because they turn a durable pump sale into repeat revenue.
MiniMed Fit and Vivera
The Fit patch pump and Vivera algorithm are pipeline products expected to launch in the U.S. in 2027.
International and U.S. mix
This mix is based on fiscal 2026 net sales by market geography. U.S. growth accelerated in early 2027 due to the Flex launch.
What could break the thesis
CGM rebate pressure
High impact · High oddsMonitoring products are moving into the pharmacy channel, where pricing can be shaped by rebates. MiniMed says rivals have broad pharmacy coverage and can offer enhanced rebates. If MiniMed has to match those rebates, growth could come with weaker margins.
Sensor mix lowers profit
High impact · Medium oddsSensors are growing fast, but MiniMed says they have historically carried lower profit margins than insulin pumps and other consumables. That means the fastest growing product line can still hurt the profit rate. The company needs manufacturing scale and premium features to offset this.
Stand alone cost creep
Medium impact · Medium oddsMiniMed became a public company in March 2026. It still relies on Medtronic for transition services and manufacturing arrangements. The old carve out cost base may not show the full cost of being independent.
Pipeline milestone charges
Medium impact · High oddsMiniMed anticipates a $162 million charge once the Fit patch pump is commercialized. These types of one time payouts can weigh on reported earnings even as product launches drive revenue.
In one breath
What does MiniMed Group do?
MiniMed makes diabetes devices and supplies. Its systems include insulin pumps, sensors, infusion sets, reservoirs, smart insulin pens, and dosing software.
Why does Medtronic still matter to MMED?
MiniMed used to be the diabetes business for Medtronic and became public in March 2026. Medtronic still owns about 90 percent of the shares and provides transition services, so future divestment and separation costs matter.
What is the biggest growth driver for MiniMed?
The biggest driver is getting more users onto MiniMed systems and selling more sensors to that base. New product launches like the MiniMed Flex are also accelerating new pump sales.
Why are investors worried about MiniMed margins?
Sensors are growing fast, but they have lower profit margins than pumps and some other supplies. The pharmacy channel can also create tougher pricing because competitors use rebates.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 6, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
